Abstract: A method and composition for treating hypertrophic scars so as to reduce the size and approve the appearance of scars comprises applying to the scar a composition comprising a film-forming carrier such as a Collodion which contains one or more active ingredients such as a topical steroid, silicone gel and vitamin E. Novel compositions using the Collodion film-forming carrier are also useful to treat a variety of adverse skin disorders.
Abstract: An endless belt in which a fibrous material is dispersed in a substantially uniform manner all over an endless elastic body layer is provided. A non-woven tape is impregnated with a polyurethane elastomer material liquid and wound and layered on a supporting belt, and then, after curing the polyurethane elastomer material liquid to form an elastic body, it is removed from supporting belt.
Abstract: The use of acetyl L-carnitine and its pharmacologically acceptable salts is disclosed for producing a composition suitable for controlling mood disorders mainly in young individuals who are not affected by permanent pathological CNS disturbances.
Abstract: Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an anti-oxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.
Type:
Grant
Filed:
April 14, 1999
Date of Patent:
January 1, 2002
Assignees:
Novartis AG, LTS Lohmann Therapie-Systeme GmbH Co. KG
Inventors:
Bodo Asmussen, Michael Horstmann, Kai Köpke, Henricus L. G. M. Tiemessen, Steven Minh Dinh, Paul M. Gargiulo
Abstract: A cosmetic or dermatological composition, comprising:
an aqueous phase dispersed in an oily phase with a silicone emulsifying agent, wherein the viscosity of the composition, measured with a Rheomat 180 viscometer at a shear rate of 200 s−1 and at 25° C., ranges from 3 Pa.s (30 poises) to 20 Pa.
Abstract: Germicidal composition for incorporation into polymeric materials molded to form germicidally protected conveyor components used for food handling. Germicidally protected conveyor components are also provided.
Type:
Grant
Filed:
July 30, 1999
Date of Patent:
December 11, 2001
Assignee:
Ram Belts & Chains, Inc.
Inventors:
Mohan L. Sanduja, Carl Horowitz, Mohammed Kamruzzaman, Paul Thottathil, Earl A. Ramsey
Abstract: The invention relates to anhydrous compositions that are useful as UV-light screens for mammalian skin. Such compositions comprise octocrylene, octyldodecyl neopentanoate, and a C1-C4 alcohol vehicle. The invention also relates to methods of inhibiting or preventing UV light-induced skin damage by administering an effective amount of such a composition to the skin of a mammal in need of such inhibition or protection.
Type:
Grant
Filed:
June 16, 2000
Date of Patent:
November 27, 2001
Assignee:
Schering-Plough HealthCare Products, Inc.
Abstract: The present invention relates to an isosorbide dinitrate-containing patch, in which an adhesive layer comprising an adhesive composition is formed on a flexible support, and the adhesive composition consists of an acrylic-based adhesive (A), a polyvinyl acetate-based adhesive (B), a plasticizing component (C) and isosorbide dinitrate (D), and satisfies the following weight ratios (1) through (3) of each of the components:
(1) A:B=70:30 to 10:90,
(2) the weight ratio of the component C based on the adhesive composition is 10 to 40% by weight, and
(3) the weight ratio of the component D based on the adhesive composition is 20 to 35% by weight.
Provided is a patch excellent in percutaneous absorption, handleability, resistance to skin irritation, sustained release, adhesivity, etc.
Abstract: Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an antioxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.
Abstract: Methods of treating diseases of ocular tissues expressing the nuclear receptor PPAR&ggr;, by inhibiting the inflammatory response, the neovascularization and angiogenesis, and programmed cell death (apoptosis) in these target tissues, comprising administering to a human or animal in need of treatment an effective amount of a compound that modifies the activity of PPAR&ggr;, or pharmaceutically acceptable salts and solvates thereof.
Type:
Grant
Filed:
June 28, 1999
Date of Patent:
November 13, 2001
Assignee:
Photogenesis, Inc.
Inventors:
Harrihar A. Pershadsingh, Daniel E. Levy
Abstract: An improved method of treatment for anxiety and/or depression provides a quicker and more robust anxiolytic/antidepressant activity to a patient suffering from depression. The method comprises the concurrent administration of effective doses of certain azapirones, such as buspirone, given in a manner that suppresses formation of the 1-(2-pyrimidinyl)piperazine metabolite; and a 5-HT1A autosomal receptor antagonist, such as pindolol.
Abstract: The invention includes a patch and method for transdermal delivery of bupropion base. In the method of this invention, a patient is administered a bupropion base in an amount effective to alleviate withdrawal symptoms and to prevent or reduce craving of nicotine in said patient. Alternatively, an effective amount of bupropion base is delivered to alleviate depression in a patient or to treat obesity. A transdermal patch includes a bupropion base. The bupropion base can be mixed with an acceptable pharmaceutical carrier.
Type:
Grant
Filed:
May 2, 2000
Date of Patent:
November 6, 2001
Assignee:
Peierce Management LLC
Inventors:
Kamal K. Midha, Hans E. Junginger, Mark Hirsh
Abstract: The invention relates to cosmetic composition comprising a fluorescent-effective amount of at least one fluorescent brightener, in combination with a cosmetically acceptable vehicle. The compositions of the invention can be used as color cosmetics and skin treatment products, to replenish the skin's natural fluorescent glow.
Abstract: Disclosed are cosmetic compositions, including lipsticks, comprising from 0.01% to about 50%, by weight, of cylindrical crystalline vitamin B3 particles having a particle size distribution such that at least about 70% of the crystalline particles have a height to width ratio greater than 1; from about 1% to about 90%, by weight, of an emollient component; from about 1% to about 90%, by weight, of a solidifying agent; and from about 1% to about 90%, on an anhydrous basis, of a color. The compositions provide improved skin feel of crystalline vitamin B3 compounds when applied to skin.
Type:
Grant
Filed:
December 28, 1999
Date of Patent:
October 30, 2001
Assignee:
The Procter & Gamble Company
Inventors:
Michael Lee Vatter, David Andrew Jakubovic
Abstract: Methods and apparatus for improving administration of drugs through the use of heat and other physical means. The present invention relates to the use of heat and other physical means in conjunction with specially designed dermal drug delivery systems, conventional commercial dermal drug delivery systems, or drugs delivered into a sub-skin depot site via injection and other methods to alter, mainly increase, the drug release rate from the dermal drug delivery systems or the depot sites to accommodate certain clinical needs.
Abstract: Methods and apparatus for improving administration of drugs through the use of heat and other physical means. The present invention relates to the use of heat and other physical means in conjunction with specially designed dermal drug delivery systems, conventional commercial dermal drug delivery systems, or drugs delivered into a sub-skin depot site via injection and other methods to alter, mainly increase, the drug release rate from the dermal drug delivery systems or the depot sites to accommodate certain clinical needs.
Abstract: A novel topical anesthetic preparation is characterized by improved transdermal absorption and efficacy. In a preferred embodiment, the topical preparation contains at least one local anesthetic agent and at least two melting point depressing agents. Also provided is a two-phase liquid composition that contains aqueous and oil phases, the oil phase having a relatively high concentration of a local anesthetic agent to enhance transdermal absorption and efficacy when incorporated into a topical anesthetic preparation. A preferred topical anesthetic preparation includes lidocaine or tetracaine, thymol or menthol, and ethyl alcohol or isopropyl alcohol. The preparation is expected to be safe and effective in obtaining transdermal anesthesia on intact skin and mucous membrane of adults, children, infants and newborns.
Type:
Grant
Filed:
July 19, 1999
Date of Patent:
October 9, 2001
Assignee:
The University of Georgia Research Foundation, Inc.
Abstract: A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterized in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen.
Type:
Grant
Filed:
December 18, 1998
Date of Patent:
October 9, 2001
Assignee:
Monash University
Inventors:
Barry Leonard Reed, Timothy Matthias Morgan, Barrie Charles Finnin
Abstract: A form-fitting cast-on enclosure arrangement has parallel chucking surfaces for the fixing of metallic workpieces with irregular contours to be processed. A process is provided for the manufacturing and separating of the enclosure arrangement. The enclosure arrangement is made of plastic material and consists of several spaced ribs which are connected by webs. The enclosure arrangement has the advantage that workpieces with irregular contours can be enclosed in a cost-effective and fast manner and can be finished or repaired.
Type:
Grant
Filed:
May 17, 1993
Date of Patent:
October 9, 2001
Assignee:
MTU Motoren-und Turbinen-Union Muenchen GmbH
Abstract: Cosmetic or pharmaceutical preparations which are distinguished by an effective content of one or more monomeric or homo- or heterodimeric or homo- or heterotrimeric or homo- or heterotetrameric oligopeptides, where these oligopeptides are based on a structure Asn-Ser-Leu-Asp-Phe SEQ ID NO: 1 as homo- or heteromonomer.
Type:
Grant
Filed:
September 23, 1998
Date of Patent:
October 2, 2001
Assignee:
Beiersdorf Aktiengesellschaft
Inventors:
Uwe Schönrock, Heiner Max, Vincent J. Hearing